-
Je něco špatně v tomto záznamu ?
Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP)
M. Markowicz-Piasecka, J. Huttunen, A. Montaser, SK. Adla, S. Auriola, M. Lehtonen, KM. Huttunen
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
294227, 294229, 307057, 311939
Academy of Finland
503/3-015-01/503-31-001-19-00
Uniwersytet Medyczny w Lodzi
CZ.02.2.69/0.0/0.0/20_079/0017783
European Social Fund
Biocenter Kuopio
Biocenter Finland
NLK
Directory of Open Access Journals
od 2000
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
PubMed Central
od 2007
Europe PubMed Central
od 2007
ProQuest Central
od 2000-03-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2007-01-01
Health & Medicine (ProQuest)
od 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
PubMed
34299347
DOI
10.3390/ijms22147727
Knihovny.cz E-zdroje
- MeSH
- ABC transportér z rodiny G, člen 2 metabolismus MeSH
- antivirové látky farmakologie MeSH
- apoptóza účinky léků MeSH
- endoteliální buňky pupečníkové žíly (lidské) MeSH
- ganciklovir farmakologie MeSH
- lidé MeSH
- methotrexát farmakologie MeSH
- MFC-7 buňky MeSH
- nádorové buněčné linie MeSH
- nádorové proteiny metabolismus MeSH
- nádory prsu farmakoterapie metabolismus MeSH
- proteiny spojené s mnohočetnou rezistencí k lékům metabolismus MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Efflux transporters, namely ATP-binding cassette (ABC), are one of the primary reasons for cancer chemoresistance and the clinical failure of chemotherapy. Ganciclovir (GCV) is an antiviral agent used in herpes simplex virus thymidine kinase (HSV-TK) gene therapy. In this therapy, HSV-TK gene is delivered together with GCV into cancer cells to activate the phosphorylation process of GCV to active GCV-triphosphate, a DNA polymerase inhibitor. However, GCV interacts with efflux transporters that are responsible for the resistance of HSV-TK/GCV therapy. In the present study, it was explored whether GCV and its more lipophilic derivative (1) could inhibit effluxing of another chemotherapeutic, methotrexate (MTX), out of the human breast cancer cells. Firstly, it was found that the combination of GCV and MTX was more hemocompatible than the corresponding combination with compound 1. Secondly, both GCV and compound 1 enhanced the cellular accumulation of MTX in MCF-7 cells, the MTX exposure being 13-21 times greater compared to the MTX uptake alone. Subsequently, this also reduced the number of viable cells (41-56%) and increased the number of late apoptotic cells (46-55%). Moreover, both GCV and compound 1 were found to interact with breast cancer resistant protein (BCRP) more effectively than multidrug-resistant proteins (MRPs) in these cells. Since the expression of BCRP was higher in MCF-7 cells than in MDA-MB-231 cells, and the cellular uptake of GCV and compound 1 was smaller but increased in the presence of BCRP-selective inhibitor (Fumitremorgin C) in MCF-7 cells, we concluded that the improved apoptotic effects of higher MTX exposure were raised mainly from the inhibition of BCRP-mediated efflux of MTX. However, the effects of GCV and its derivatives on MTX metabolism and the quantitative expression of MTX metabolizing enzymes in various cancer cells need to be studied more thoroughly in the future.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025329
- 003
- CZ-PrNML
- 005
- 20211026133922.0
- 007
- ta
- 008
- 211013s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms22147727 $2 doi
- 035 __
- $a (PubMed)34299347
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Markowicz-Piasecka, Magdalena $u Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151 Lodz, Poland
- 245 10
- $a Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP) / $c M. Markowicz-Piasecka, J. Huttunen, A. Montaser, SK. Adla, S. Auriola, M. Lehtonen, KM. Huttunen
- 520 9_
- $a Efflux transporters, namely ATP-binding cassette (ABC), are one of the primary reasons for cancer chemoresistance and the clinical failure of chemotherapy. Ganciclovir (GCV) is an antiviral agent used in herpes simplex virus thymidine kinase (HSV-TK) gene therapy. In this therapy, HSV-TK gene is delivered together with GCV into cancer cells to activate the phosphorylation process of GCV to active GCV-triphosphate, a DNA polymerase inhibitor. However, GCV interacts with efflux transporters that are responsible for the resistance of HSV-TK/GCV therapy. In the present study, it was explored whether GCV and its more lipophilic derivative (1) could inhibit effluxing of another chemotherapeutic, methotrexate (MTX), out of the human breast cancer cells. Firstly, it was found that the combination of GCV and MTX was more hemocompatible than the corresponding combination with compound 1. Secondly, both GCV and compound 1 enhanced the cellular accumulation of MTX in MCF-7 cells, the MTX exposure being 13-21 times greater compared to the MTX uptake alone. Subsequently, this also reduced the number of viable cells (41-56%) and increased the number of late apoptotic cells (46-55%). Moreover, both GCV and compound 1 were found to interact with breast cancer resistant protein (BCRP) more effectively than multidrug-resistant proteins (MRPs) in these cells. Since the expression of BCRP was higher in MCF-7 cells than in MDA-MB-231 cells, and the cellular uptake of GCV and compound 1 was smaller but increased in the presence of BCRP-selective inhibitor (Fumitremorgin C) in MCF-7 cells, we concluded that the improved apoptotic effects of higher MTX exposure were raised mainly from the inhibition of BCRP-mediated efflux of MTX. However, the effects of GCV and its derivatives on MTX metabolism and the quantitative expression of MTX metabolizing enzymes in various cancer cells need to be studied more thoroughly in the future.
- 650 _2
- $a ABC transportér z rodiny G, člen 2 $x metabolismus $7 D000070997
- 650 _2
- $a antivirové látky $x farmakologie $7 D000998
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a nádory prsu $x farmakoterapie $x metabolismus $7 D001943
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a ganciklovir $x farmakologie $7 D015774
- 650 _2
- $a endoteliální buňky pupečníkové žíly (lidské) $7 D061307
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a MFC-7 buňky $7 D061986
- 650 _2
- $a methotrexát $x farmakologie $7 D008727
- 650 _2
- $a proteiny spojené s mnohočetnou rezistencí k lékům $x metabolismus $7 D027425
- 650 _2
- $a nádorové proteiny $x metabolismus $7 D009363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Huttunen, Johanna $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 700 1_
- $a Montaser, Ahmed $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 700 1_
- $a Adla, Santosh Kumar $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland $u Institute of Organic Chemistry and Biochemistry (IOCB), Czech Academy of Sciences, Flemingovo Namesti 542/2, 160 00 Prague, Czech Republic
- 700 1_
- $a Auriola, Seppo $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 700 1_
- $a Lehtonen, Marko $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 700 1_
- $a Huttunen, Kristiina M $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 14 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34299347 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133928 $b ABA008
- 999 __
- $a ok $b bmc $g 1714397 $s 1145836
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 22 $c 14 $e 20210720 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a 294227, 294229, 307057, 311939 $p Academy of Finland
- GRA __
- $a 503/3-015-01/503-31-001-19-00 $p Uniwersytet Medyczny w Lodzi
- GRA __
- $a CZ.02.2.69/0.0/0.0/20_079/0017783 $p European Social Fund
- GRA __
- $a Biocenter Kuopio $p Biocenter Finland
- LZP __
- $a Pubmed-20211013